Status:

COMPLETED

Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI

Lead Sponsor:

Vanderbilt University

Collaborating Sponsors:

Mallinckrodt

Conditions:

Pulmonary Vascular Disorder

Eligibility:

All Genders

18+ years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of the study is to measure RV ejection fraction (RVEF), pulmonary flow, and pulmonary perfusion before and after exposure to inhaled nitric oxide in patients with pulmonary arterial hypert...

Eligibility Criteria

Inclusion

  • Patients age 18 or older of the Vanderbilt Center for Pulmonary Vascular Disease. Vasodilator-responsive patients will be identified based on prior response to inhaled nitric oxide during invasive right heart catheterization
  • Healthy subjects age 18 or older not known to have cardiopulmonary disease

Exclusion

  • Standard conventional contraindications for cardiac magnetic resonance (CMR) imaging
  • Allergy or contraindication to Magnevist (gadopentetate dimeglumine) contrast
  • Concurrent intravenous epoprostenol infusion in whom performance of CMR is cumbersome
  • Pregnant women

Key Trial Info

Start Date :

July 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2017

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT02220023

Start Date

July 1 2014

End Date

February 1 2017

Last Update

February 13 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232